Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.

摘要: Over the last decade, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) have been firmly established as essential drugs for treatment of metastatic colorectal cancer (CRC). Cetuximab and panitumumab approved by American European drug agencies. This review aims at exploring main outcomes clinical studies performed during their development, from phase I to III trials, hence giving a comprehensive scientific rational up-to-date evidence sustaining use these drugs. Many areas are still under active investigation such administration schedules, efficacy in comparison with bevacizumab, role adjuvant therapy, molecular predictors, management side effects.